Evidence map›Paper›PMID 34819133›Full record

ArticleJournal of cheminformatics2021

Development of a chemogenomics library for phenotypic screening.

Bryan Dafniet, Natacha Cerisier, Batiste Boezio, Anaelle Clary, Pierre Ducrot, Thierry Dorval, Arnaud Gohier, David Brown, Karine Audouze, Olivier Taboureau

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bryan DafnietUniversité de Paris, INSERM U1133, CNRS UMR8251, 75006, Paris, France.
Natacha CerisierUniversité de Paris, INSERM U1133, CNRS UMR8251, 75006, Paris, France.
Batiste BoezioUniversité de Paris, INSERM U1133, CNRS UMR8251, 75006, Paris, France.
Anaelle ClaryInstitut de Recherche Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
Pierre DucrotInstitut de Recherche Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
Thierry DorvalInstitut de Recherche Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
Arnaud GohierInstitut de Recherche Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
David BrownInstitut de Recherche Servier, 125 Chemin de Ronde, 78290, Croissy-sur-Seine, France.
Karine AudouzeUniversité de Paris, INSERM UMR S-1124, 75006, Paris, France.
Olivier TaboureauUniversité de Paris, INSERM U1133, CNRS UMR8251, 75006, Paris, France. olivier.taboureau@u-paris.fr.ORCID http://orcid.org/0000-0001-7081-2491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of advanced technologies in cell-based phenotypic screening, phenotypic drug discovery (PDD) strategies have re-emerged as promising approaches in the identification and development of novel and safe drugs. However, phenotypic screening does not rely on knowledge of specific drug targets and needs to be combined with chemical biology approaches to identify therapeutic targets and mechanisms of actions induced by drugs and associated with an observable phenotype. In this study, we developed a system pharmacology network integrating drug-target-pathway-disease relationships as well as morphological profile from an existing high content imaging-based high-throughput phenotypic profiling assay known as "Cell Painting". Furthermore, from this network, a chemogenomic library of 5000 small molecules that represent a large and diverse panel of drug targets involved in diverse biological effects and diseases has been developed. Such a platform and a chemogenomic library could assist in the target identification and mechanism deconvolution of some phenotypic assays. The usefulness of the platform is illustrated through examples.

Indexed as

Chemical biologyChemogenomicsNetwork pharmacologyPhenotypic drug discoveryPhenotypic screeningSystem pharmacology network

Identifiers

PMID34819133
PMCPMC8611952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.